Hansa Medical appoints Göran Arvidson as CFO

Hansa Medical AB strengthens its organization by recruiting Göran Arvidson as CFO of the company. Göran Arvidson will assume his position immediately.

Göran Arvidson, born 1960, has significant experience from the life science sector. He has been Vice President and CFO of Swedish Orphan Biovitrum AB (publ) and has held senior positions with Procordia AB and Pharmacia AB. He has a MBA from Stockholm School of Economics. Göran Arvidson owns no shares in Hansa Medical.

For further information, please contact:
Hansa Medical AB
Fredrik Lindgren, President and CEO
Mobile: 46 705 61 61 77
E-mail: fredrik.lindgren@hansamedical.com

About Hansa Medical AB
Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory conditions. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser


About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.